Related references
Note: Only part of the references are listed.A cost comparison of amikacin therapy with bedaquiline, for drug-resistant tuberculosis in the UK
Kavina Manalan et al.
JOURNAL OF INFECTION (2020)
MDR/XDR-TB management of patients and contacts: Challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network
Giovanni Battista Migliori et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2020)
Worldwide Effects of Coronavirus Disease Pandemic on Tuberculosis Services, January-April 2020
Giovanni Battista Migliori et al.
EMERGING INFECTIOUS DISEASES (2020)
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: A global feasibility study
Onno Akkerman et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2019)
Treatment of Drug-Resistant Tuberculosis An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Payam Nahid et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
Sergey Borisov et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation
Roland Diel et al.
EUROPEAN RESPIRATORY JOURNAL (2014)
Multidrug-Resistant Tuberculosis and Culture Conversion with Bedaquiline
Andreas H. Diacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Cost of multi drug resistance tuberculosis in Germany
R. Diel et al.
RESPIRATORY MEDICINE (2014)
Treatment Practices, Outcomes, and Costs of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis, United States, 2005-2007
Suzanne M. Marks et al.
EMERGING INFECTIOUS DISEASES (2014)
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
D. Falzon et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Daily 300 mg dose of linezolid for the treatment of intractable multidrug-resistant and extensively drug-resistant tuberculosis
Won-Jung Koh et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2009)
German recommendations on health economic evaluation: Third and updated version of the Hanover Consensus
J. -Matthias Graf von der Schulenburg et al.
VALUE IN HEALTH (2008)
Share Paper
